Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David MacDonald

Showing results (91-100 of 141) with videos related to

Pageof 15
Sort By:
Journal of Medical Radiation Sciences|August 1, 2015
Relationship of computed tomography perfusion and positron emission tomography to tumour progression in malignant gliomaTimothy P C Yeung, Slav Yartsev, Ting-Yim Lee, et al.
Clinical Transplantation|February 20, 2014
Low birthweight and risk of albuminuria in living kidney donorsDanielle Berglund, David MacDonald, Scott Jackson, et al.
Investigational New Drugs|October 31, 2003
A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytomaKarl Bélanger, David MacDonald, Gregory Cairncross, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2016
Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin LymphomaMichinori Ogura, Kensei Tobinai, Kiyohiko Hatake, et al.
The Lancet. Oncology|February 14, 2014
Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 studyAndrew Davies, Francesco Merli, Biljana Mihaljevic, et al.
Neuroimage|May 18, 2005
Automated 3-D extraction and evaluation of the inner and outer cortical surfaces using a Laplacian map and partial volume effect classificationJune Sic Kim, Vivek Singh, Jun Ki Lee, et al.
British Journal of Haematology|May 11, 2021
A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study)Mathias J Rummel, Ann Janssens, David MacDonald, et al.
Journal of Comparative Effectiveness Research|April 20, 2026
Health care resource use in the management of patients with relapsed/refractory diffuse large B-cell lymphoma - Canadian perspectiveKimberly Guinan, Mathieu Pelletier, Monika Ham, et al.
Neuro-Oncology|September 10, 2008
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131Michael A Vogelbaum, Brian Berkey, David Peereboom, et al.
The Lancet. Haematology|May 7, 2017
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trialAndrew Davies, Francesco Merli, Biljana Mihaljević, et al.
Pageof 15

Showing results (91-100 of 141) with videos related to

Sort By:
Pageof 15
Journal of Medical Radiation Sciences|August 1, 2015
Relationship of computed tomography perfusion and positron emission tomography to tumour progression in malignant gliomaTimothy P C Yeung, Slav Yartsev, Ting-Yim Lee, et al.
Clinical Transplantation|February 20, 2014
Low birthweight and risk of albuminuria in living kidney donorsDanielle Berglund, David MacDonald, Scott Jackson, et al.
Investigational New Drugs|October 31, 2003
A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytomaKarl Bélanger, David MacDonald, Gregory Cairncross, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2016
Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin LymphomaMichinori Ogura, Kensei Tobinai, Kiyohiko Hatake, et al.
The Lancet. Oncology|February 14, 2014
Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 studyAndrew Davies, Francesco Merli, Biljana Mihaljevic, et al.
Neuroimage|May 18, 2005
Automated 3-D extraction and evaluation of the inner and outer cortical surfaces using a Laplacian map and partial volume effect classificationJune Sic Kim, Vivek Singh, Jun Ki Lee, et al.
British Journal of Haematology|May 11, 2021
A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study)Mathias J Rummel, Ann Janssens, David MacDonald, et al.
Journal of Comparative Effectiveness Research|April 20, 2026
Health care resource use in the management of patients with relapsed/refractory diffuse large B-cell lymphoma - Canadian perspectiveKimberly Guinan, Mathieu Pelletier, Monika Ham, et al.
Neuro-Oncology|September 10, 2008
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131Michael A Vogelbaum, Brian Berkey, David Peereboom, et al.
The Lancet. Haematology|May 7, 2017
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trialAndrew Davies, Francesco Merli, Biljana Mihaljević, et al.
Pageof 15